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Lung transplantation (LTx) is a valid therapeutic option for selected patients with end-stage lung disease. HLA-E seems to play a
major role in the immune response to different viral infections and to affect transplantation outcome, in Hematopoietic Stem Cell
Transplantation, for example. Two nonsynonymous alleles, HLA-E∗01:01 and HLA-E∗01:03, have functional differences, involving
relative peptide affinity, cell surface expression, and potential lytic activity of NK cells. The aim of this retrospective study was
to determine the impact of these two alleles for LTx recipients on anti-HLA alloimmunization risk, overall survival, and chronic
rejection (CLAD). HLA-E was genotyped in 119 recipients who underwent LTx from 1998 to 2010 in a single transplantation center.
In univariate analysis, both HLA-E homozygous states were associated with impaired overall survival compared to heterozygous
HLA-E alleles (𝑝 = 0.01). In multivariate analysis, HLA-E∗01:03 allele showed increased CLAD occurrence when compared to
homozygous HLA-E∗01:01 status (HR: 3.563 (CI 95%, 1.016–12), 𝑝 = 0.047). HLA-E allele did not affect pathogen infection or the
production of de novo DSA. This retrospective study shows an uninvestigated, deleterious association of HLA-E alleles with LTx
and requires verification using a larger cohort.
1. Introduction
Lung transplantation (LTx) is a valid therapeutic option for
selected patients with end-stage lung disease. Unfortunately,
posttransplant prognosis is hampered by the occurrence of
chronic lung allograft dysfunction (CLAD) which is highly
prevalent and remains the major limitation to long-term
survival and functional outcome in LTx compared to other
solid-organ transplants [1]. CLAD commonly reflects a bron-
chiolar obstruction defining a bronchiolitis obliterans syn-
drome (BOS). Recently, another phenotype of CLAD with a
predominant restrictive pattern has been identified and called
restrictive allograft syndrome (RAS) [2]. BOS and probably
RAS are considered to be a multistep injury remodeling
phenomenon targeted by recurrent immunologic events such
as acute rejection and the development of de novo Donor
Specific Antibodies (DSA). Several nonimmunological risk
factors have been proposed, although not yet widely accepted
as cytomegalovirus pneumonitis, bacterial/fungal/non-CMV
viral infections, and persistent neutrophil influx and seques-
tration.Also, various genetic factors have been identified such
as TGF- (Transforming Growth Factor-) B1, Toll-Like Recep-
tor (TLR), and IL- (Interleukin-) 17. However, confirmation
was not consistent across all studied cohorts [3].
Recently, we showed that HLA-G genetic polymorphism
could be associated with LTx outcome, especially with
CLAD occurrence [4]. HLA-G is a nonclassical HLA class I
molecule, closely related to HLA-E: the HLA-Emolecule also
plays a crucial role in inflammatory and adaptive immune
responses. HLA-E binds preferentially to the inhibitory
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CD94/NKG2A and activating CD94/NKG2C (which lacks
ITIM motif) receptors, selectively expressed on NK cells and
a subset of CTL cells, modulating their cell-mediated activity
[5]. Furthermore, HLA-E has also been showed to react with
CD8 T cells expressing the conventional T Cell Receptor
(TCR), suggesting that HLA-E involvement in the adaptive
immune system responses is mediated by T cells [6].
HLA-EmRNA is expressed in most tissues [7], but its cell
surface expression appears to be controlled by the binding of
a range of different peptides, such as signal peptides derived
from classical and nonclassical MHC class I molecules,
stress protein peptides, and peptides derived from different
pathogens [8, 9]. Thus, physiologically, HLA-E is expressed
at the cell surface of endothelial cells, T and B lymphocytes,
monocytes, and macrophages [10].
As HLA-G, HLA-E displays limited polymorphism with
21 alleles listed in the IMG/HLA database (release 3.23.0),
including 9 proteins. HLA-E∗01:01 and HLA-E∗01:03 are
the main alleles observed, with similar frequencies (∼50%)
in different populations [11–14]. They differ at codon 107
(R/G) and encode HLA-ER (E∗01:01) and HLA-EG (E∗01:03)
proteins. Functional differences between these two isoforms
involve relative peptide affinity, cell surface expression, and
potential lytic activity of NK cells [15]. Indeed, HLA-E∗01:03
protein is more thermally stable, exhibits higher cell surface
expression, and is a potentially stronger inhibitor of the NK
cell’s lytic activity compared to HLA-E∗01:01 [15].
A limited number of studies, with conflicted results,
investigated into the influence of HLA-E genotype on trans-
plantation outcomes. Although it is very difficult to show
an impact of HLA-E polymorphism in HSCT, because of a
limited amount of clinical data (cohort size, patient treatment
differences), the majority of studies supported an association
between the HLA-E∗01:03 allele and a lower risk of graft-
versus-host disease, decreased mortality, and greater disease-
free survival suggesting graft-versus-leukemia (GVL) effect
after Hematopoietic Stem Cell Transplantation (HSCT) [16–
20].
Control of HLA-E cell surface expression by bacterial
or viral infections and particularly human CMV is well
established [21]. One study showed that CMV-associated
HLA-E-restricted T cell alloreactivity was tightly regulated by
NK receptors [22]. Furthermore, a recent study demonstrated
that CMV-associated HLA-E-restricted T cells from a kidney
transplant recipient recognize and lyse allogenic endothe-
lial cells independently of their CMV status and HLA-
E genotype, supporting a potentially detrimental HLA-E
alloreactivity [23]. Interestingly, HLA-E molecules expressed
in transgenic mice elicited an alloantigenic reaction indis-
tinguishable from classical MHC class I molecules [24].
Finally, natural HLA antibodies directed against HLA-E have
been detected in the sera of nonalloimmunized healthy male
donors, probably induced by cross-reactive bacterial antigens
and/or peptides derived from ingested food or allergens [25].
Since immunosuppressed lung transplant patients are
particularly sensitive to infection and HLA sensitization, we
speculated that HLA-E genotype could have an influence on
the lung protection/allograft rejection balance.
Considering the immunotolerogenic properties of HLA-
E, the main objectives of this study were to determine
the impact of HLA-E alleles in a cohort of 138 adult LTx
recipients on overall survival, disease-free survival (with and
withoutCLAD), and viral and bacterial infection and onHLA
sensitization.
2. Material and Methods
2.1. Study Design and Patient Characteristics. We conducted
a retrospective single-center study based on adult patients
who underwent LTx at the Marseille Lung Transplant Center
between December 1998 and December 2010. Patients who
had less than 90-day survival or who were lost to follow-up
were excluded. There were 138 adult LTx recipients (mean
(SD) age: 39.3 (16.3) years, 64 women and 55 men) eligible
for analysis.
Patients received a first lung transplant (26 single LTx; 112
bilateral LTx) for an initial diagnosis of cystic fibrosis (43%),
emphysema (25%), pulmonary fibrosis (20%), or another
diagnosis (12%). The mean age at transplant procedure was
39.3 (13.3) years. The mean follow-up time was 37.2 months
(CI: 10.8–63.2months). HLA-A,HLA-B,HLA-DR, andHLA-
DQ mismatching between donor and recipient were 56%,
82%, 68%, and 53%, respectively. De novo post-LTx DSA
were detected in 51 recipients (38%) using Luminex single-
antigen flow beads. Forty-two, 26, 11, and 11 post-LTx DSA
were detected atMonth 1,M3,M12, andM24, respectively [3].
2.2. Posttransplant Clinical Management. Immunosuppres-
sion and prophylaxis: all recipients received a similar stan-
dardized immunosuppressive regimen in accordance with
our institutional protocols. Induction therapy consisted of
intravenous administration of rabbit anti-thymocyte glob-
ulins (Pasteur Merieux, Lyon, France) given for the first
3 postoperative days (except when daily lymphocyte count
was below 200/mm3 and when there were cytomegalovirus
(CMV) and/or EBV mismatches, i.e., seronegative recipient
and seropositive donor). A high dose of methylprednisolone
was additionally administered (6mg/kg/d Day 1, 2mg/kg/d
Day 2 and Day 3, and 1mg/kg/d thereafter). The standard
triple maintenance immunosuppressive regimen consisted
of cyclosporin (adjusted to maintain whole blood trough
levels varying between 200 and 250 ng/mL) or tacrolimus
after 2003 (adjusted to maintain whole blood trough levels
varying between 8 and 12 ng/mL), azathioprine (1mg/kg/d)
or mycophenolate mofetil after 2003 in 5 patients (adjusted
to a white blood cell count above 4000mm3), and steroids
(prednisone) tapered to 0.25mg/kg/d over the first 3 months
and stopped if possible around 12 months after surgery.
Episodes of acute cellular allograft rejection were treated
with intravenous methylprednisolone (5mg/kg/d for 3 con-
secutive days) and then rapidly reduced. All CMV-positive
recipients were treated with IV ganciclovir switched to oral
valganciclovir as soon as possible for prophylaxis over the
first 15 days after transplantation. All CMV-mismatched
recipients (seronegative recipient and seropositive donor)
were treated with IV ganciclovir or oral valganciclovir when
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available for prophylaxis for the first 3 postoperative months.
CMV-negative recipients who received a graft from a negative
donor did not receive antiviral prophylaxis. All recipients
were screened weekly for CMV infection with a polymerase
chain reaction assay and pp65 antigenemia for the first 12
weeks, monthly thereafter, and when clinically indicated.
Pulmonary function tests (PFTs) were routinely con-
ducted at our center on a monthly basis for the first 12
postoperative months, at 2-month intervals in the second
year, and at 3-month intervals thereafter. In addition, PFTs
were conducted when patients had clinical symptoms or
a decline in home spirometry values of at least 10% on 2
consecutive days. Spirometry was measured in a constant
volume (830 L) whole body plethysmograph (MasterLab,
Jaeger, Wurzburg, Germany) and included measurement of
forced vital capacity (FVC), FEV
1
, residual volume (RV),
and total lung capacity (TLC). Forced expiratory flow rate
between 25% and 75% of FVC (FEF
25–75) was obtained from
the best flow-curve volume. The baseline FEV
1
value was
calculated as the average of the 2 best FEV
1
values at least
3 weeks apart. Baseline values of TLC and FEV
1
/FVC were
defined as the average of the 2 measurements obtained at the
same time as the best 2 FEV
1
measurements.
The diagnosis of CLAD included both BOS and RAS phe-
notypes. BOS was defined according to the ISHLT guidelines
[19]. RAS was defined as an irreversible decline in TLC to
<90% of baseline for more than 3 weeks [2].
2.3. HLA-E Genotyping. A home-made primer extension
method described in Julie et al., 2011, was used to simulta-
neously analyze 5 SNPs of the HLA-E gene in 119 patients to
detect HLA-E∗01:01, HLA-E∗01:02, HLA-E∗01:03, and HLA-
E∗01:04 alleles [11]. Nineteen acid nucleic samples were either
lost (10) or degraded (9).
Briefly, the HLA-E multiplex PCR coamplified two PCR
fragments (exons 1-2 by forward primer TGGTAGATG-
GAACCCTCCTTT and reverse primer GTGAATCTG-
GGACCCGAAG and exon 3 by forward primer GTG-
GGCGGGACTGACTAAG and reverse primer AGTAGC-
CCTGTGGACCCTCT) encompassing three and two SNPs,
respectively. The multiplex PCR was performed on 200 and
75 ng of genomicDNA, respectively, in a final volume of 25𝜇L
containing 1x PCR buffer, 1.5mM MgCl
2
, 0.2mM of each
dNTP, and 0.1 units of Taq DNA-polymerase (Invitrogen,
Cergy-Pontoise, France) and a defined concentration of each
primer. Amplification was carried out as follows: 1 cycle at
95∘C for 5min; 30 cycles at 95∘C for 30 s, 63∘C for 45 s,
and 72∘C for 75 s; and 1 cycle at 72∘C for 7min. After
control on 2% (w/v) agarose gel, 15 𝜇L of PCR product
was incubated with 5 units of shrimp alkaline phosphatase
and 1 unit of exonuclease-I (Euromedex, Souffelweyersheim,
France) for 1 h at 37∘C followed by 15min at 80∘C to remove
unincorporated primers and dNTPs.
The second step involved the incorporation of a fluo-
rescent dNTP into extension-primers annealed upstream or
downstream to each SNP. This multiplex extension reaction
including five forward or reverse extension-primers (48T-
AGTGTGGAAATACTTCAAGGAGTG to detect polymor-
phism C/G in codon 66, 10T-CCGCACAGATTTTCCGAG-
TGAA to detect polymorphism C/T in codon 77, 25T-CTG-
CGGACGCTGCG to detect polymorphismC/G in codon 83,
41T-CGCGGAGGAAGCGCC to detect polymorphism A/G
in codon 107, and 41T-GCATGTGTCTTCCAGGTAGGCTC
to detect polymorphism G/A in codon 157) was performed
using the SNaPshot kit (Applied Biosystems, Courtaboeuf,
France) according to the manufacturer’s protocol in a final
volume of 10 𝜇L containing 3 𝜇L of the PCR product, 5𝜇L
of SNaPshot mix, and extension-primers. The reaction was
programed as follows: 25 cycles at 95∘C for 10 s, 50∘C for
5 s, and 60∘C for 30 s. The product of the extension reaction
(10 𝜇L)was purifiedwith 1 unit of SAP for 1 h at 37∘C, followed
by 15min at 80∘C for enzyme inactivation.
The fluorescence and size of the extended products were
determined by capillary electrophoresis on an ABI PRISM
3130XL genetic analyzer (Applied Biosystems) using POP-7
polymer and a 36 cmcapillary array. Capillary electrophoresis
was performed according to the manufacturer’s protocol.
Data were analyzed using GENEMAPPER v4.0 with
specific detection parameters. Using an in-house computer
program, output files (.txt) exported from GENEMAPPER
4.0 were automatically formatted into files readable by the
“Phenotype” application of the GENE[RATE] computer tool
package [26].
HLA-G and UTR genotyping data were from [4].
2.4. Studied Variables. Variables applied in univariate and
multivariable analyses were grouped into four categories:
(1) Preoperative donor variables: donor age, gender,
CMV status, and classical HLA type.
(2) Preoperative and postoperative recipient variables:
recipient age, gender, initial diagnosis, HLA type and
HLA Donor Specific Antibodies (DSA), CMV status
and bacterial infection at M1 and M3, HLA-E, and
HLA-G polymorphism.
(3) Preoperative donor-recipient matching: age, gender,
CMVmismatch, and HLA mismatch.
(4) Intraoperative variables: ischemic time and type of
procedure (single versus bilateral LTx).
2.5. Statistical Analyses. Missing data led to the exclusion
of the concerned sample from further analyses. No multiple
imputations were used in this study.
HLA-G and HLA-E Global Linkage Disequilibrium and
HLA-E frequencies were estimated using an EM algorithm
implemented in the GENE[RATE] computer tools. Devia-
tions from Hardy-Weinberg equilibrium (HWE) were tested
using a nested likelihood model.
Median values and ranges were used for continuous
variables and percentages for categorical variables. For each
continuous variable, the study cohort was initially split into
quartiles and into two groups at the median.
Analysis using the Kruskal-Wallis test, Fisher’s exact
test, and Chi-square test was applied to determine clinical
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Table 1: (a) Univariate analysis of death risk factors. (b) Univariate
analysis of CLAD occurrence risk factors.
(a)
Variables 𝑝 value
Diseases other than cystic fibrosis <0.001
HLA class II DSA <0.001
HLA-G∗01:04∼UTR3 0.001
Older recipients 0.001
CLAD occurrence 0.002
HLA class I DSA 0.03
HLA-B mismatch 0.03
(b)
Variables 𝑝 value
HLA-DQ mismatch 0.002
HLA class I DSA 0.008
Diseases other than cystic fibrosis 0.01
HLA-DR mismatch 0.01
Single lung transplantation 0.03
HLA-G∗01:04∼UTR3 0.03
Older recipients 0.05
significance wherever required, in particular for any rele-
vance between HLA-E alleles and the status of CMV infec-
tion.
The primary endpoints of this study were overall survival
(OS) and disease-free survival (DFS). OS was defined as the
interval between the date of transplantation and last follow-
up visit or death. DFS was defined as the time interval from
transplantation to the first event, either the diagnosis of
CLAD or death without diagnosis of CLAD. The Kaplan-
Meier method was used to estimate OS and freedom from
CLAD. The log-rank test was used to assess the univariate
effects on OS and DFS. For all analyses, 𝑝 < 0.05 was
considered statistically significant.
Multivariate analyses were performed using Fine and
Gray’s proportional hazards regression model.
All analyses were performed using SPSS 15.0 software
(SPSS Inc., Chicago, IL) and the cmprsk package (developed
by Gray, June 2001) on R2.3.0 software (http://www.R-project
.org/).
3. Results
3.1. Conditions Associated with Overall Survival and Allograft
Function. Overall survival of the LTx population was 74%
and 68% at 12 and 24 months, respectively (median survival,
7 years). In univariate analysis, the conditions associated with
better survival were an initial diagnosis of cystic fibrosis (CF)
compared to other indications, HLA class II DSA detected
at M3 and/or M12, HLA-G∗01:04∼UTR3 haplotype, the
younger age of the recipient, absence of CLAD occurrence,
the number of recipient/donor mismatches at the B locus,
and HLA class I DSA detected at M3 and/orM12 (Table 1(a)).
During the study period, 29 LTx recipients developed CLAD
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Figure 1: Survival curves in LTx recipients according to the presence
of heterozygousHLA-E (in green) compared to homozygousHLA-E
(homozygous HLA-E∗01:01 in light grey, homozygous HLA-E∗01:03
in blue) (log-rank test, 𝑝 = 0.01).
(including 5 patients (17%) with RAS and 24 (83%) with
BOS), corresponding to a proportion of 8%, 21%, and 30%
of the cohort at 1, 2, and 3 years after LTx, respectively.
The major risks for CLAD were HLA class I DSA detected
at M3 and/or M12, recipient/donor mismatches at HLA-DR
and HLA-DQ loci, the single lung transplant procedure, the
non-CF population, and carrying the HLA-G∗01:04∼UTR3
haplotype (Table 1(b)).
3.2. HLA-E Allelic Frequencies. A total of 3 HLA-E genotypes
were observed in these patients (Table 2). HomozygousHLA-
E∗01:01 was detected in 38/119 (32%) patients, homozygous
HLA-E∗01:03 was detected in 24/119 (20%), and heterozygous
HLA-E was detected in 57/119 (48%). HLA-E frequency dis-
tribution was in Hardy-Weinberg equilibrium. HLA-E allele
and genotype frequencies were also concordant with previ-
ously published data showing a relatively equal distribution
between HLA-E∗01:01 and HLA-E∗01:03 in Western Europe
[11]. Analysis of two-locus Global Linkage Disequilibrium
(GLD) showed that the HLA-E alleles are not in significant
GLD with HLA-G or UTR loci.
3.3. Impact of HLA-E Alleles and Genotypes on LTx Out-
come. HLA-E genotype was not associated with patient
characteristics (Table 2). HLA-E∗01:01/01:03 heterozygous
state was associated with survival advantage (𝑝 = 0.01)
when compared to HLA-E∗01:01 or HLA-E∗01:03 homozy-
gous states. The two-year survival rate was 80% ± 8% for
HLA-E heterozygous genotypes and 50% ± 8% and 50% ±
10% for homozygous HLA-E∗01:01 and homozygous HLA-
E∗01:03 states, respectively (Figure 1). HLA-E∗01:03 allele was
associated with CLAD occurrence (Figure 2). The two-year
freedom fromCLAD ratewas 44%±25% for theHLA-E∗01:03
allele and 73.4%±8% for the homozygous HLA-E∗01:01 state.
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Table 2: Baseline comparison of distribution and risk factors for 119 patients who underwent LTx according to HLA-E genotypes.
E∗01:01/∗01:01 E∗01:01/∗01:03 E∗01:03/∗01:03 p E∗01:01/∗01:01 E∗01:03 allele p
Genotypes frequency (𝑁, %) 38 (31.9) 57 (47.9) 24 (20.2) 38 (31.9) 81 (68.1)
Male (𝑁, %) 15 (40) 28 (49) 12 (50) 0.60 15 (39.5) 40 (49) 0.33
Age of recipient (SD) 39.1 (14.2) 40.23 (13) 39.6 (12) 0.92 39.1 (14.2) 40 (13) 0.72
Initial disease 0.33 0.91
Emphysema (𝑁, %) 10 (26.3) 11 (19.3) 10 (41.7) 10 (26.3) 21 (25.9)
Fibrosis (𝑁, %) 8 (21.1) 8 (14) 5 (20.8) 8 (21.1) 13 (16.1)
Cystic fibrosis (𝑁, %) 14 (36.8) 28 (49.1%) 6 (25%) 14 (36.8) 34 (42.1)
Others (𝑁, %) 6 (15.8) 10 (17.5%) 3 (12.5) 6 (15.8) 13 (16)
Transplant procedure 0.58 0.92
Lung and heart transplantation (𝑁, %) 1 (2.6) 0 (0) 1 (4.2) 1 (2.6) 1 (1.2)
Single lung transplantation (𝑁, %) 8 (21.1) 14 (24.6) 4 (16.7) 8 (21.1) 18 (22.2)
Bilateral lung transplantation (𝑁, %) 29 (76.3) 43 (75.4) 19 (79.2) 29 (76.3) 62 (76.5)
CMV status
D+/R− (𝑁, %) 6 (16.2) 7 (12.3) 4 (17.4) 0.83 6 (16.2) 11 (13.8) 0.78
D+/R+ or − (𝑁, %) 19 (51) 31 (54) 9 (40) 0.46 19 (51) 40 (50) 0.88
D+ or −/R+ (𝑁, %) 22 (58) 36 (63) 12 (50) 0.54 22 (58) 48 (59) 0.88
Mismatch HLA/6 (𝑁) 5.03 5 4.83 0.9 5.03 4.95 0.90
Infection at M1 (𝑁, %) 8 (53.3) 16 (47.1%) 2 (25) 0.49 8 (53.3) 18 (42.9) 0.48
Infection at M3 (𝑁, %) 6 (46.2) 7 (38.9) 5 (50) 0.83 6 (46.2) 12 (42.9) 0.84
Infection in first year (𝑁, %) 16 (42) 32 (56) 11 (45.8) 0.37 16 (42.1) 43 (53.1) 0.26
DSA at M1 (𝑁, %) 7 (63.6) 13 (81.3) 5 (83.3) 0.51 7 (63.5) 18 (81.8) 0.25
DSA at M3 (𝑁, %) 6 (66.7) 8 (66) 3 (60) 1 6 (66.7) 11 (64.7) 0.92
CLAD occurrence (𝑁, %) 5 (22.7) 20 (40.8) 7 (58.3) 0.06 5 (22.7) 27 (44.3) 0.02
BOS (𝑁, %) 5 (23.8) 16 (32.7) 6 (22.2) 0.31 5 (23.8) 22 (36.1) 0.02
RAS (𝑁, %) 0 (0) 4 (8.2) 1 (8.3) 0.41 0 (0) 5 (8.2) 0.32
Overall survival (median, year) 2.37 3.7 2.6 0.01
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Figure 2: Freedom from CLAD in LTx recipients according to the
presence of homozygous HLA-E∗01:01 (in blue) compared to HLA-
E∗01:03 alleles (in green) (log-rank test, 𝑝 = 0.02).
Cox proportional regression hazards modeling showed
that the main risk factors for CLAD were a noncystic fibrosis
initial diagnosis (𝑝 < 0.001), HLA-E∗01:03 alleles carriers
Table 3: Main risk factors for CLAD according to Cox regression
multivariate analysis on recipient diagnosis, HLA-G∗01:04∼UTR3
haplotype, andHLA-E∗01:03 allele (HR, hazard ratio; CI, confidence
interval).
Estimated HR (95% CI) 𝑝 value
Diagnosis
Cystic fibrosis Baseline 0.000
Emphysema 8.612 (3.113–23.824) 0.000
Fibrosis 1.515 (0.362–6.335) 0.569
Others 2.897 (0.822–10.214) 0.098
HLA-G∗01:04∼UTR3 2.567 (0.889–7.412) 0.071
HLA-E∗01:03 3.563 (1.016–12.488) 0.047
(𝑝 = 0.047), and HLA-G∗01:04∼UTR3 carriers (𝑝 =
0.071). The relative risks of CLAD were 8.612 for emphysema
compared to cystic fibrosis patients (CI 95%, 3.13–23.824),
3.563 in recipients carrying HLA-E∗01:03 allele compared to
recipients who did not carry it (CI 95%, 1.016–12), and 3.037
in recipients carrying HLA-G∗01:04∼UTR3 compared to
recipientswhodid not carry it (CI 95%, 0.889–7.412) (Table 3).
None of the HLA-E alleles were significantly associated
with the different clinical variables, such as bacterial infection
at M1 or M3 and DSA detection at M1 and M3 (Table 2).
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4. Discussion
This is the first study to show that HLA-E polymorphisms
could be implicated in survival andCLADoccurrence in LTx.
The two homozygous HLA-E states are associated with worse
survival compared to the heterozygous state. These alleles
however contribute differentially as HLA-E∗01:03 allele is
correlated to CLAD occurrence in multivariate analysis.
Although the exact pathogenesis of CLAD remains
unknown, studies indicate that BOS begins with epithelial
injury of the airways due to a variety of factors such as viral
infection, autoimmune disease, and alloreactivity response,
followed by an inflammatory reaction that leads to obliter-
ation of the airways [3]. HLA-E is an immunomodulatory
molecule that can function as both an immune-tolerogenic
and immune-activating molecule and plays a dual role in
natural and acquired immune responses.
The HLA-E-peptide complex can act as ligand for the
CD94/NKG2 receptors expressed on the surface natural
killer cells and represents a restriction element for the TCR.
Although the two alleles only differ by a single amino acid
in alpha 2 domain of the HLA-E heavy chain, HLA-E∗01:03
is characterized by a stronger affinity for various peptides
and a higher thermal stability thanHLA-E∗01:01, inducing its
higher cell surface expression in PBMC or other cells [27].
These differences might influence the affinities for the dif-
ferent activator or inhibitor receptors, might induce different
intracellular signaling, and might have an impact on the cel-
lular immune response in the context of transplantation [28].
HLA-E has the ability to bind non-self-antigen and self-
antigen, among which peptides derived from the leader
sequences of classical and nonclassical HLAmolecules. HLA-
E and HLA-G, both categorized as nonclassical class I HLA,
share immunosuppressive properties and immunological cell
targets; furthermore, HLA-E has the highest affinity for the
HLA-G leader peptide. These observations back quite a close
relationship between these molecules, but this coordination
remains unclear. For instance, in the context of pregnancy,
HLA-E, binding an HLA-G peptide signal, interacts with
CD94/NKG2C activating receptors to activate NK cells lysis
of trophoblast cells during placental invasion, leading to
tissue remodeling [29]. At a genetic level, the low number
of coding SNPs in both HLA-E and HLA-G loci could
suggest that amino acidmodifications have serious functional
consequences. However, HLA-G and HLA-E are not in GLD.
Furthermore, the impact of HLA-G∗01:04∼UTR3 on CLAD
occurrence seems to be independent of the HLA-E∗01:03
allele; finally, contrary to HLA-G alleles, HLA-E∗01:03 was
not associated with an increase in anti-HLA alloimmuniza-
tion, suggesting that HLA-E and HLA-G have both differen-
tial involvements and pathways. Thus, another hypothesis to
explain the low level of coding modification in both HLA-E
and HLA-G loci is that they lead to amino acid modifications
with little functional consequences but that they are linked
to SNPs in the regulatory region involved in quantitative
expression.
Considering HLA-E and pathogen infections, HLA-E
can bind to different viral peptides derived from CMV, the
Epstein-Barr virus, the human immunodeficiency virus, the
influenza virus, and Hepatitis C virus. A few studies have
linked reactivation of CMV with organ rejection [30]. CMV
infection in post-LTx is considered a risk factor for BOS
[30, 31]. The CMV immune evasion protein, UL40, when
complexed with HLA-E, can modulate NK cell functions
via interactions with the CD94-NKG2A receptors, leading
to viral evasion [31]. Recently, it has been suggested that
latent CMV infection-mediated increase in the proportion of
NKG2C+ NK cells may prime NK cell cytotoxicity and could
be beneficial in preventing the progression and development
of hematologic malignancies characterized by high HLA-E
expression [32]. This effect, dependent potentially on HLA-
E alleles, may be deleterious for transplantation occurrence.
Furthermore, the UL40-derived sequence can also be
immunogenic, eliciting robust CD8+ T cell responses.
Recently, CMV UL-40-specific T cells were detected in the
peripheral blood of LTx recipients and were significantly
associatedwith allograft dysfunction, such as BOS [33].These
cells were first identified between 6 and 12 months after
transplant, a period that coincides with the cessation of
antiviral prophylaxis and the highest risks for CMV reac-
tivation, suggesting an antigen-driven expansion restricted
preferentially by HLA-E. These cells could lyse a large array
of allogenic target cells and directly damage the allograft [34].
In contrast, HLA-E can promote specific HLA-E-restricted
CD8+ Treg cells that inhibit antiviral effector CD8+ T cells,
diminishing virus control [35].
In this retrospective study, CMV reactivation data were
unavailable. Mismatch CMV (D−/R− versus D+/R− or + and
D+ or −/R+) were not associated with CLAD occurrence and
overall survival (𝑝 = 0.8 and 𝑝 = 0.7, resp.). None of the
homozygous or heterozygous HLA-E alleles with a positive
CMV recipient and/or donor showed a statistical difference
on survival and CLAD occurrence compared to the same
HLA-E alleles with a negative CMV recipient and donor (𝑝 =
0.8 and 𝑝 = 0.7) (data not shown). The percentage of death
(55%) was similar between positive CMV recipient and/or
donor and negative CMV donor and recipient, whatever
homozygous HLA-E alleles. These results can be explained
by the small size of this retrospective monocentric cohort.
Furthermore, reactivation of other viruses such as respiratory
virus could be more relevant than CMV reactivation [36].
T cells are also able to recognize HLA-E binding pep-
tides from bacteria such as Mycobacterium tuberculosis,
Salmonella, and Listeria monocytogenes. In an unrelated
allogenic stem cell transplantation study, homozygous HLA-
E∗01:01 was identified as a risk for the occurrence of severe
bacterial but not viral infections [16]. None of the HLA-E
alleles were associated with a higher risk of bacterial infection
at M1 and M3.
Another hypothesis is that HLA-E∗01:03 could lead to
more efficient activation of CD8+ T cells alloreactivity. This
mechanism has been suggested in a few related or unrelated
stem cell allograft studies, showing that homozygous HLA-
E∗01:03 induced a significant graft-versus-leukemia effect
[17–19, 37]. In this context, HLA-E∗01:03 recipient may
preferentially bind nonstandard minor histocompatibility
antigen (mHag) peptides that can react with T cell activating
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receptors [18, 19, 37]. Thus, as for the GVL effect, this HLA-
E dependent, alloreactive cellular process could specifically
generate lung tissue inflammation. Furthermore, it has been
shown that HLA-E exhibits alloantigenic properties that are
indistinguishable from classical HLA class I molecules when
expressed in HLA-E∗01:03 transgenic mice [24].
In summary, these data could be explained by the func-
tional properties of the two HLA-E alleles in peptide affinity,
cell surface expression, and potential lytic activity by NK
cells or T cells. Therefore, a heterozygous status would offset
the two homozygous states, each allele bringing benefits
and risks to the overall survival of recipients via different
mechanisms. For example, HLA-E∗01:03 could promote cel-
lular alloreactivity mechanisms, triggered or not by viral
infection via different receptors. In contrast, HLA-E∗01:01
could promote severe bacterial infection. Anyway, the impact
of these two alleles in lung transplantation is concordant with
the maintenance of these two alleles based on a balancing
selection, meaning that there is a heterozygote advantage for
individuals that are heterozygous at theHLA-E locus [38, 39].
Finally, the mechanism by which HLA-E alleles may
promote CLAD and decrease long-term survival after LTx
remains to be elucidated.Themajor limitation of this investi-
gation is that it is a single-retrospective study and for certain
analyses the patient cohort was small. It is possible that a few
confounding factors not explored in this study may modify
its interpretation. Furthermore, in the same way, a potential
role of the donor’s genotype and the possible interactions
with the recipient’s genotype could be studied. Thus, this
association of HLA-E polymorphism with LTx occurrence
needs verification using a larger cohort.
Abbreviations
LTx: Lung transplantation
CLAD: Chronic lung allograft dysfunction
FEV
1
: Forced Expiratory Volume measured
during the first second
FVC: Forced vital capacity
DSA: Donor Specific Antibodies
BOS: Bronchiolitis obliterans syndrome
RAS: Restrictive allograft syndrome
CTL: Cytotoxic T-Lymphocytes
OS: Overall survival
DFS: Disease-free survival
ITIM: ImmunoTyrosine Inhibitor Module
CT: Computed Tomography
PFTs: Pulmonary function tests
RV: Residual volume
TLC: Total lung capacity
CMV: Cytomegalovirus
SD: Standard Deviation
HSCT: Hematopoietic Stem Cell Transplantation
TGF: Transforming Growth Factor
TLR: Toll-Like Receptor
IL: Interleukin
D: Donor
R: Recipient.
Competing Interests
The authors have no conflict of interests to disclose.
Acknowledgments
This study was funded by the Etablissement Franc¸ais du
Sang, Marseille, France. This work was supported in part by
“Vaincre la Mucoviscidose” through Funding “TP1008.”
References
[1] R. D. Yusen, J. D. Christie, L. B. Edwards et al., “The registry
of the international society for heart and lung transplantation:
thirtieth adult lung and heart-lung transplant report—2013;
focus theme: age,” Journal of Heart and Lung Transplantation,
vol. 32, no. 10, pp. 965–978, 2013.
[2] G. M. Verleden, G. Raghu, K. C. Meyer, A. R. Glanville, and P.
Corris, “A new classification system for chronic lung allograft
dysfunction,” Journal of Heart and Lung Transplantation, vol. 33,
no. 2, pp. 127–133, 2014.
[3] G. M. Verleden, R. Vos, B. Vanaudenaerde et al., “Current views
on chronic rejection after lung transplantation,” Transplant
International, vol. 28, no. 10, pp. 1131–1139, 2015.
[4] J. Di Cristofaro, M. Reynaud-Gaubert, F. Carlini et al., “HLA-
G∗01:04∼UTR3 recipient correlates with lower survival and
higher frequency of chronic rejection after lung transplanta-
tion,” American Journal of Transplantation, vol. 15, no. 9, pp.
2413–2420, 2015.
[5] V. M. Braud, D. S. J. Allan, C. A. O’Callaghan et al., “HLA-E
binds to natural killer cell receptors CD94/NKG2A, B and C,”
Nature, vol. 391, no. 6669, pp. 795–799, 1998.
[6] G. Pietra, C. Romagnani, M. Falco et al., “The analysis of the
natural killer-like activity of human cytolytic T lymphocytes
revealed HLA-E as a novel target for TCR alpha/beta-mediated
recognition,” European Journal of Immunology, vol. 31, no. 12,
pp. 3687–3693, 2001.
[7] H. Heinrichs andH. T. Orr, “HLA non-A,B,C class I genes: their
structure and expression,” Immunologic Research, vol. 9, no. 4,
pp. 265–274, 1990.
[8] N. Lee, M. Llano, M. Carretero et al., “HLA-E is a major
ligand for the natural killer inhibitory receptor CD94/NKG2A,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 95, no. 9, pp. 5199–5204, 1998.
[9] J. Michae¨lsson, C. Teixeira de Matos, A. Achour, L. L. Lanier, K.
Ka¨rre, andK. So¨derstro¨m, “A signal peptide derived fromhsp60
binds HLA-E and interferes with CD94/NKG2A recognition,”
Journal of Experimental Medicine, vol. 196, no. 11, pp. 1403–1414,
2002.
[10] G. Kochan, D. Escors, K. Breckpot, and D. Guerrero-Setas,
“Role of non-classical MHC class I molecules in cancer
immunosuppression,” OncoImmunology, vol. 2, no. 11, Article
ID e26491, 2013.
[11] D. C. Julie, S. Buhler, C. Frassati et al., “Linkage disequilibrium
between HLA-G∗0104 and HLA-E∗0103 alleles in Tswa Pyg-
mies,” Tissue Antigens, vol. 77, no. 3, pp. 193–200, 2011.
[12] A. Antoun, S. Jobson, M. Cook, P. Moss, and D. Briggs, “Ethnic
variability in human leukocyte antigen-E haplotypes,” Tissue
Antigens, vol. 73, no. 1, pp. 39–45, 2009.
[13] L. Carvalho dos Santos, L. V. Tureck, P. F. Wowk et al., “HLA-
E polymorphisms in an Afro-descendant Southern Brazilian
8 Journal of Immunology Research
population,” Human Immunology, vol. 74, no. 2, pp. 199–202,
2013.
[14] E. C. Castelli, C. T. Mendes-Junior, A. Sabbagh et al., “HLA-
E coding and 3’ untranslated region variability determined by
next-generation sequencing in two West-African population
samples,”Human Immunology, vol. 76, no. 12, pp. 945–953, 2015.
[15] L. C. Sullivan, C. S. Clements, J. Rossjohn, and A. G. Brooks,
“Themajor histocompatibility complex class Ib molecule HLA-
E at the interface between innate and adaptive immunity,”Tissue
Antigens, vol. 72, no. 5, pp. 415–424, 2008.
[16] R. Tamouza, V. Rocha, M. Busson et al., “Association of HLA-
E polymorphism with severe bacterial infection and early
transplant-relatedmortality inmatched unrelated bonemarrow
transplantation,” Transplantation, vol. 80, no. 1, pp. 140–144,
2005.
[17] R. Tamouza,M. Busson, V. Rocha et al., “Homozygous status for
HLA-E*0103 confers protection from acute graft-versus-host
disease and transplant-related mortality in HLA-matched sib-
ling hematopoietic stem cell transplantation,” Transplantation,
vol. 82, no. 11, pp. 1436–1440, 2006.
[18] M.Danzer, H. Polin, J. Pro¨ll et al., “Clinical significance ofHLA-
E∗0103 homozygosity on survival after allogeneic hematopoi-
etic stem-cell transplantation,” Transplantation, vol. 88, no. 4,
pp. 528–532, 2009.
[19] E. Hosseini, A. P. Schwarer, A. Jalali, and M. Ghasemzadeh,
“The impact of HLA-E polymorphisms on relapse following
allogeneic hematopoietic stem cell transplantation,” Leukemia
Research, vol. 37, no. 5, pp. 516–519, 2013.
[20] L. Wieten, N. M. Mahaweni, C. E. M. Voorter, G. M. J. Bos, and
M. G. J. Tilanus, “Clinical and immunological significance of
HLA-E in stem cell transplantation and cancer,”Tissue Antigens,
vol. 84, no. 6, pp. 523–535, 2014.
[21] M. Ulbrecht, S. Martinozzi, M. Grzeschik et al., “Cutting edge:
the human cytomegalovirus UL40 gene product contains a
ligand for HLA-E and prevents NK cell-mediated lysis,” The
Journal of Immunology, vol. 164, no. 10, pp. 5019–5022, 2000.
[22] G. Pietra, C. Romagnani, P. Mazzarino et al., “HLA-E-restricted
recognition of cytomegalovirus-derived peptides by human
CD8+ cytolytic T lymphocytes,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100, no.
19, pp. 10896–10901, 2003.
[23] M. Allard, P. Tonnerre, S. Nedellec et al., “HLA-E-restricted
cross-recognition of allogeneic endothelial cells by CMV-
associated CD8 T cells: a potential risk factor following trans-
plantation,” PLoS ONE, vol. 7, no. 11, article e50951, 2012.
[24] R. Pacasova, S. Martinozzi, H.-J. Boulouis et al., “Cell-surface
expression and alloantigenic function of a human nonclassical
class I molecule (HLA-E) in transgenic mice,” The Journal of
Immunology, vol. 162, no. 9, pp. 5190–5196, 1999.
[25] M. H. Ravindranath, T. Pham, M. Ozawa, and P. I. Terasaki,
“Antibodies to HLA-E may account for the non-donor-specific
anti-HLA class-Ia antibodies in renal and liver transplant
recipients,” International Immunology, vol. 24, no. 1, pp. 43–57,
2012.
[26] J. Nunes, Generate: Tools for Analysis and Handling of Data
with Ambiguities, Laboratory of Anthropology, Genetics and
Peopling History, University of Geneva, Geneva, Switzerland,
2006, http://geneva.unige.ch/generate/.
[27] N. Lauterbach, L.Wieten,H. E. Popeijus et al., “Peptide-induced
HLA-E expression in human PBMCs is dependent on peptide
sequence and the HLA-E genotype,” Tissue Antigens, vol. 85, no.
4, pp. 242–251, 2015.
[28] M.A. Pabo´n, C. E. Navarro, J. C.Osorio et al., “Impact of human
leukocyte antigen molecules E, F, and G on the outcome of
transplantation,” Transplantation Proceedings, vol. 46, no. 9, pp.
2957–2965, 2014.
[29] M. Llano, N. Lee, F. Navarro et al., “HLA-E-bound peptides
influence recognition by inhibitory and triggeringCD94/NKG2
receptors: Preferential response to an HLA-G-derived non-
amer,” European Journal of Immunology, vol. 28, no. 9, pp. 2854–
2863, 1998.
[30] T. Martinu, D.-F. Chen, and S. M. Palmer, “Acute rejection and
humoral sensitization in lung transplant recipients,” Proceedings
of the American Thoracic Society, vol. 6, no. 1, pp. 54–65, 2009.
[31] G. P. Westall, A. Michaelides, T. J. Williams, G. I. Snell,
and T. C. Kotsimbos, “Bronchiolitis obliterans syndrome and
early human cytomegalovirus DNAaemia dynamics after lung
transplantation,”Transplantation, vol. 75, no. 12, pp. 2064–2068,
2003.
[32] A. B. Bigley, K. Rezvani, N. Shah et al., “Latent CMV infection
enhances anti-tumor cytotoxicity through accumulation of
NKG2C+NK-cells in healthy humans,”Clinical & Experimental
Immunology, 2016.
[33] L. C. Sullivan, G. P.Westall, J. M. L.Widjaja et al., “The presence
of HLA-E-restricted, CMV-specific CD8+ T cells in the blood
of lung transplant recipients correlates with chronic allograft
rejection,” PLoS ONE, vol. 10, no. 8, Article ID e0135972, 2015.
[34] C. Romagnani, G. Pietra, M. Falco et al., “Identification of
HLA-E-specific alloreactive T lymphocytes: a cell subset that
undergoes preferential expansion in mixed lymphocyte culture
and displays a broad cytolytic activity against allogeneic cells,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, no. 17, pp. 11328–11333, 2002.
[35] T. A. W. Holderried, P. A. Lang, H.-J. Kim, and H. Can-
tor, “Genetic disruption of CD8+ Treg activity enhances the
immune response to viral infection,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 110, no.
52, pp. 21089–21094, 2013.
[36] R. A. Vilchez, J. Dauber, and S. Kusne, “Infectious etiology of
bronchiolitis obliterans: the respiratory viruses connection—
myth or reality?” American Journal of Transplantation, vol. 3,
no. 3, pp. 245–249, 2003.
[37] E. Hosseini, A. P. Schwarer, and M. Ghasemzadeh, “Do human
leukocyte antigen E polymorphisms influence graft-versus-
leukemia after allogeneic hematopoietic stem cell transplanta-
tion?”ExperimentalHematology, vol. 43, no. 3, pp. 149–157, 2015.
[38] D. E. Geraghty,M. Stockschleader, A. Ishitani, and J. A. Hansen,
“Polymorphism at the HLA-E locus predates most HLA-A and
-B polymorphism,”Human Immunology, vol. 33, no. 3, pp. 174–
184, 1992.
[39] C. Grimsley andC.Ober, “Population genetic studies ofHLA-E:
evidence for selection,” Human Immunology, vol. 52, no. 1, pp.
33–40, 1997.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
